Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial
Cesare Gridelli, Eckhard Kaukel, Vanesa Gregorc et al. · Journal of Thoracic Oncology · 2007
Cited by 47 works. doi:10.1097/jto.0b013e318031cd62 Open-access PDF
Authors
- Cesare Gridelli
- Eckhard Kaukel
- Vanesa Gregorc
- Maria Rita Migliorino
- Thomas R Müller
- Christian Manegold
- Adolfo Gino Favaretto
- Andrea Angelo Martoni
- Orazio Caffo
- Alexander H. Schmittel
- Antônio Rossi
- Francesco Paolo Russo
- Patrick M. Peterson
- María del Mar Muñoz
- Martin Reck
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- SEER Cancer Statistics Review, 1975-2003
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
- Action of 2',2'-difluorodeoxycytidine on DNA synthesis.